311 related articles for article (PubMed ID: 34551586)
21. Pharmacokinetics of the Cardioprotective Drug Dexrazoxane and Its Active Metabolite ADR-925 with Focus on Cardiomyocytes and the Heart.
Jirkovský E; Jirkovská A; Bureš J; Chládek J; Lenčová O; Stariat J; Pokorná Z; Karabanovich G; Roh J; Brázdová P; Šimůnek T; Kovaříková P; Štěrba M
J Pharmacol Exp Ther; 2018 Mar; 364(3):433-446. PubMed ID: 29273587
[TBL] [Abstract][Full Text] [Related]
22. Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Zhen J; Yu H; Ji H; Cai L; Leng J; Keller BB
Life Sci; 2019 Dec; 239():117070. PubMed ID: 31751580
[TBL] [Abstract][Full Text] [Related]
23. Cellular Mechanisms Mediating Exercise-Induced Protection against Cardiotoxic Anthracycline Cancer Therapy.
Dozic S; Howden EJ; Bell JR; Mellor KM; Delbridge LMD; Weeks KL
Cells; 2023 May; 12(9):. PubMed ID: 37174712
[TBL] [Abstract][Full Text] [Related]
24. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
25. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
26. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
[TBL] [Abstract][Full Text] [Related]
27. Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents.
Simůnek T; Klimtová I; Kaplanová J; Mazurová Y; Adamcová M; Sterba M; Hrdina R; Gersl V
Eur J Heart Fail; 2004 Jun; 6(4):377-87. PubMed ID: 15182761
[TBL] [Abstract][Full Text] [Related]
28. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
29. Risk-benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling.
Reichardt P; Tabone MD; Mora J; Morland B; Jones RL
Future Oncol; 2018 Oct; 14(25):2663-2676. PubMed ID: 29747541
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
31. Anthracyclines induce cardiotoxicity through a shared gene expression response signature.
Matthews ER; Johnson OD; Horn KJ; Gutiérrez JA; Powell SR; Ward MC
PLoS Genet; 2024 Feb; 20(2):e1011164. PubMed ID: 38416769
[TBL] [Abstract][Full Text] [Related]
32. Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment.
Chaudhari U; Nemade H; Wagh V; Gaspar JA; Ellis JK; Srinivasan SP; Spitkovski D; Nguemo F; Louisse J; Bremer S; Hescheler J; Keun HC; Hengstler JG; Sachinidis A
Arch Toxicol; 2016 Nov; 90(11):2763-2777. PubMed ID: 26537877
[TBL] [Abstract][Full Text] [Related]
33. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
Lyu YL; Kerrigan JE; Lin CP; Azarova AM; Tsai YC; Ban Y; Liu LF
Cancer Res; 2007 Sep; 67(18):8839-46. PubMed ID: 17875725
[TBL] [Abstract][Full Text] [Related]
34. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
35. Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers.
Henninger C; Fritz G
Cell Death Dis; 2017 Jan; 8(1):e2564. PubMed ID: 28102848
[TBL] [Abstract][Full Text] [Related]
36. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Goey AK; Schellens JH; Beijnen JH; Huitema AD
Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
[TBL] [Abstract][Full Text] [Related]
38. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759
[TBL] [Abstract][Full Text] [Related]
39. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone.
Simůnek T; Sterba M; Popelová O; Kaiserová H; Adamcová M; Hroch M; Hasková P; Ponka P; Gersl V
Br J Pharmacol; 2008 Sep; 155(1):138-48. PubMed ID: 18536744
[TBL] [Abstract][Full Text] [Related]
40. All-trans retinoic acid (ATRA) regulates key genes in the RARG-TOP2B pathway and reduces anthracycline-induced cardiotoxicity.
Hasbullah JS; Scott EN; Bhavsar AP; Gunaretnam EP; Miao F; Soliman H; Carleton BC; Ross CJD
PLoS One; 2022; 17(11):e0276541. PubMed ID: 36331922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]